Seminars in Oncology
Volume 33 , Pages 18-25 , April 2006

Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program

  • Heidi A. Lane

      Affiliations

    • Novartis Institutes For BioMedical Research, Oncology Basel, Novartis Pharma AG, Switzerland.
    • Dr Lane is an employee of Novartis Pharma AG, Basel, Switzerland.
    • ,
  • David Lebwohl

      Affiliations

    • Novartis Oncology, East Hanover, NJ.
    • Dr Lebwohl is an employee of Novartis Pharmaceuticals, East Hanover, NJ, USA.
    • Corresponding Author InformationAddress correspondence and reprint requests to: David Lebwohl, MD, Phase II/III Oncology, Novartis Oncology, One Health Plaza, East Hanover, NJ 07936, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0093-7754(06)00172-2

doi: 10.1053/j.seminoncol.2006.03.024

Seminars in Oncology
Volume 33 , Pages 18-25 , April 2006

Article Tools

* Image Usage & Resolution